Regenon 25mg Capsules UK

Dosage
Before prescribing this medication, the diagnosis of obesity caused by secondary organic causes must be excluded. Regenon 25mg Capsules UK

Obesity treatment must be done through a global approach that must include dietary, medical and psychotherapeutic methods.

Dosage

Adults and children over 12 years of age

The recommended daily dose is 1 capsule x 3 times a day.

The total daily dose should not exceed 3 Regenon capsules.

Method of administration

Regenon capsules should be swallowed whole, with a little liquid, before main meals.

The last administration should be at least 4 hours before bedtime, considering that this medication induces restlessness and insomnia.

It is recommended that treatment be administered under the supervision of a physician experienced in the treatment of obesity.

Duration of treatment

The duration of treatment is 46 weeks and should not exceed three months.

If no weight loss is observed after 3-4 weeks, therapy should be discontinued.

In the case of treatment for more than 4 weeks, the benefit should be carefully weighed against the possible risk. Even in the case of weight loss, Regenon should not be taken for more than 12 weeks.

Contraindications
– hypersensitivity to amfepramone hydrochloride or to any of the excipients listed in section 6.1.

– paroxysmal tachycardia

– tachyarrhythmias

– pheochromocytoma

– hyperthyroidism

– severe forms of angina pectoris

– angle-closure glaucoma

– pulmonary hypertension

– severe hypertension

– current or past cardiovascular or cerebrovascular diseases

– current or past psychiatric conditions (e.g. psychotic reactions) including anorexia nervosa and depression

– tendency to abuse medications, drug or alcohol addiction

– advanced atherosclerosis

– children under 12 years of age.

The combination with any other centrally active anorectic product is contraindicated, due to the increased risk of pulmonary arterial hypertension, which is potentially fatal.

Warnings
Regenon should be used with caution in the presence of:

• urethro-prostatic disease with urinary retention
• metabolic diseases (e.g. diabetes mellitus)
• hypertension
• heart disease

The use of Regenon may lead to positive test results for doping control and may further pose a health risk.

Severe cases of pulmonary arterial hypertension, often fatal, have been reported in patients receiving anorectics of this type. An epidemiological study has shown that the use of anorectics is a risk factor for the development of pulmonary arterial hypertension and that their use is associated with an increased risk of these adverse reactions.

Due to this rare but serious risk, it should be highlighted that:

• It is necessary to carefully follow the indications and duration of treatment.
• Treatment duration greater than 3 months and BMI greater than 30 kg/m2 increase the risk of pulmonary arterial hypertension.
• The onset or worsening of exertional dyspnea suggests the possibility of pulmonary arterial hypertension. In this case, treatment should be stopped immediately and the patient referred for investigation to a specialized unit.

Long-term treatment may increase the risk of pharmacological tolerance and drug dependence; in rare cases, in predisposed patients, severe psychiatric disorders may occur.